These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35078225)

  • 41. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
    Matsubara H; Kojima T; Kaneko A; Hirano Y; Ishikawa H; Hattori Y; Miyake H; Oguchi T; Takagi H; Yabe Y; Kato T; Ito T; Fukaya N; Kanayama Y; Shioura T; Hayashi M; Fujibayashi T; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Terabe K; Ishiguro N
    J Rheumatol; 2014 Aug; 41(8):1583-9. PubMed ID: 25028370
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of gender on methotrexate prescription attitudes in Italian rheumatoid arthritis patients: the MARI study.
    Giusti A; Epis OM; Migliore A; Ricioppo A; Sainaghi PP; Di Matteo L; Massarotti MS; Govoni M; Mazzone A; Traballi G; Ciarla S; Cozzi L; Roncaglione A; Muratore M; Laurenti R; Bianchi G
    Clin Exp Rheumatol; 2019; 37(6):1003-1009. PubMed ID: 31172925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessing methotrexate intolerance and its prevalence in rheumatoid arthritis: Development and validation of the MISA questionnaire.
    Vijaykumar D; Dhir V; Jain S; Pai V; Kaur J; Naidu GS; Sharma A; Khanna Sharma S; Jain S
    Int J Rheum Dis; 2021 Oct; 24(10):1294-1301. PubMed ID: 34432365
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate.
    Lertnawapan R; Chonprasertsuk S; Siramolpiwat S
    Int J Rheum Dis; 2019 Feb; 22(2):214-221. PubMed ID: 30565876
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
    Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB
    Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis.
    Hilliquin P; Renoux M; Perrot S; Puéchal X; Menkès CJ
    Br J Rheumatol; 1996 May; 35(5):441-5. PubMed ID: 8646434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice.
    Karlsson Sundbaum J; Eriksson N; Hallberg P; Lehto N; Wadelius M; Baecklund E
    Int J Rheum Dis; 2019 Jul; 22(7):1226-1232. PubMed ID: 31012257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study.
    Hakamata J; Hashiguchi M; Kaneko Y; Yamaoka K; Shimizu M; Maruyama J; Takeuchi T; Mochizuki M
    Mod Rheumatol; 2018 Jul; 28(4):611-620. PubMed ID: 29252093
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment.
    Fleischmann R; Schiff M; van der Heijde D; Ramos-Remus C; Spindler A; Stanislav M; Zerbini CA; Gurbuz S; Dickson C; de Bono S; Schlichting D; Beattie S; Kuo WL; Rooney T; Macias W; Takeuchi T
    Arthritis Rheumatol; 2017 Mar; 69(3):506-517. PubMed ID: 27723271
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
    Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis.
    Curtis JR; Palmer JL; Reed GW; Greenberg J; Pappas DA; Harrold LR; Kremer JM
    Arthritis Care Res (Hoboken); 2021 Aug; 73(8):1114-1124. PubMed ID: 32374918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.
    Atsumi T; Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Togo O; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2017 Aug; 76(8):1348-1356. PubMed ID: 28153828
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.
    van Dijkhuizen EH; Bulatović Ćalasan M; Pluijm SM; de Rotte MC; Vastert SJ; Kamphuis S; de Jonge R; Wulffraat NM
    Pediatr Rheumatol Online J; 2015; 13():5. PubMed ID: 25745368
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data.
    Kimyon G; Kalyoncu U; Kiraz S; Bes C; Coşkun N; Yağiz B; Küçükşahin O; Kanitez N; Erden A; Kiliç L; Bilgin E; Kaşifoğlu T; Emmungil H; Koca SS; Akar S; Çinar M; Yazisiz V; Ateş A; Ersözlü D; Gönüllü E; Mercan R; Ertenli İ
    Clin Exp Rheumatol; 2021; 39(4):852-858. PubMed ID: 32896266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire).
    Fatimah N; Salim B; Nasim A; Hussain K; Gul H; Niazi S
    Clin Rheumatol; 2016 May; 35(5):1341-5. PubMed ID: 27053094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
    Ideguchi H; Ohno S; Ishigatsubo Y
    J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: A single-center observational study.
    Aramaki T; Ueki Y; Kojima K; Kurushima S; Tsuji Y; Kawachi N; Iwamoto N; Ichinose K; Terada K; Eguchi K; Kawakami A
    Mod Rheumatol; 2020 Jan; 30(1):50-57. PubMed ID: 30482075
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.